Linvoseltamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Multiple Myeloma
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion ...
Regeneron announces EMA CHMP adopted positive opinion on linvoseltamab
Pharmaceuticals announced that the European Medicines Agency’s, EMA, Committee for Medicinal Products for Human Use, CHMP, has ...
Regeneron Pharmaceuticals, Inc.: Linvoseltamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Multiple Myeloma
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human ...
Regeneron Gets CHMP Backing of Linvoseltamab in Multiple Myeloma
Regeneron on Friday said the recommendation covers adults with adults with relapsed and refractory multiple myeloma who have received at least three prior therapies, including a proteasome inhibitor, ...
Regeneron's linvoseltamab gets positive EU regulatory opinion
Regeneron Pharmaceuticals (NASDAQ:REGN) said the European Medicines Agency’s Committee for Medicinal Products for Human Use ...
Investing3d
Regeneron's SWOT analysis: biotech stock faces eylea challenges, pipeline promise
1. Oncology Portfolio: The company's expanding oncology pipeline, including fianlimab (anti-LAG-3 antibody) and linvoseltamab, has caught investor attention. Fianlimab, in particular, has shown ...
pharmaphorum4d
Regeneron bids to join the BCMA bispecific camp
Regeneron has moved closer to a regulatory filing for its BCMAxCD3 bispecific antibody linvoseltamab, the first of a series of bispecifics that is spearheading its oncology pipeline. New data from ...
Investing3d
Regeneron's SWOT analysis: biotech stock faces eylea challenges, pipeline promise
1. Oncology Portfolio: The company's expanding oncology pipeline, including fianlimab (anti-LAG-3 antibody) and linvoseltamab, has caught investor attention. Fianlimab, in particular, has shown ...
pharmaphorum3d
GSK scores again with Blenrep in multiple myeloma
The aforementioned therapies and other drugs like Regeneron’s linvoseltamab are all being tested in pivotal trials as second- or third-line therapies. So, GSK’s window of opportunity with ...